Financial Performance - Corvus Pharmaceuticals reported a net loss of $4.3 million for Q2 2024, an improvement from a net loss of $6.5 million in Q2 2023[9]. - The net loss for the quarter was $4,262,000, a decrease from a net loss of $6,503,000 in the same quarter of the previous year, indicating an improvement of 34.4%[20]. - Corvus Pharmaceuticals reported total operating expenses of $5,935,000 for the three months ended June 30, 2024, compared to $5,622,000 for the same period in 2023, reflecting an increase of 5.57%[20]. - The company reported interest income of $434,000 for the quarter, compared to $403,000 in the same quarter of 2023, showing a growth of 7.69%[20]. Cash Position - The company had cash, cash equivalents, and marketable securities of $47.2 million as of June 30, 2024, up from $27.1 million at the end of 2023[8]. - Cash, cash equivalents, and marketable securities increased to $47,246,000 as of June 30, 2024, up from $27,149,000 at the end of 2023, representing a growth of 74.1%[21]. - Corvus anticipates full-year 2024 net cash used in operating activities to be between $24 million and $27 million, projecting a cash balance of $31 million to $34 million by December 31, 2024[8]. - The company expects to fund operations into the fourth quarter of 2025, with estimated net cash used in operating activities for 2024 being a critical focus[19]. Research and Development - Research and development expenses for Q2 2024 totaled $4.1 million, slightly higher than $4.0 million in the same period of 2023[8]. - In the Phase 1/1b trial of soquelitinib for relapsed T cell lymphoma, 39% of evaluable patients (9 out of 23) achieved objective responses, including 26% with complete responses[4]. - The ongoing Phase 1 clinical trial of soquelitinib in atopic dermatitis aims to enroll 64 patients, with initial results showing clinical activity in three evaluable patients[3]. - Corvus plans to initiate a Phase 3 registrational trial for soquelitinib in patients with relapsed peripheral T cell lymphoma in Q3 2024[4]. - Corvus Pharmaceuticals is conducting a Phase 1b/2 clinical trial for mupadolimab in combination with pembrolizumab for patients with advanced head and neck cancers and NSCLC[17]. - Corvus Pharmaceuticals anticipates launching a registrational Phase 3 clinical trial for soquelitinib for PTCL, with specific timelines and patient enrollment targets yet to be detailed[19]. - The company expects to present interim data from the Phase 1 clinical trial of soquelitinib in atopic dermatitis in Q4 2024[3]. Investments and Equity - The company's investment in Angel Pharmaceuticals decreased slightly to $15,404,000 from $16,123,000, a decline of 4.44%[21]. - Corvus Pharmaceuticals has a total of 59,710,265 shares used to compute net loss per share for the quarter, compared to 47,497,414 shares in the same quarter of 2023[20]. - Corvus Pharmaceuticals has a 49.7% equity stake in Angel Pharmaceuticals, with a 7% equity reserved for issuance under the Angel ESOP[18]. Regulatory Designations - The FDA has granted Orphan Drug Designation for soquelitinib for the treatment of T cell lymphoma, and it has received Fast Track designation for relapsed or refractory peripheral T cell lymphoma[4]. - Corvus completed a registered direct offering in Q2 2024, generating $30.3 million in net proceeds[8].

Soquelitinib registrational Phase 3 clinical trial in PTCL advancing toward initial enrollment in Q3 2024 Fast track designation underscores unmet need for patients with relapsed or refractory PTCL, an indication with poor overall outcomes and no approved drugs based on randomized trials BURLINGAME, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and ...

BURLINGAME, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone acces ...

BURLINGAME, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, and Jeffrey Arcara, chief business officer, will conduct one-on-one meetings with investors and present a corporate overview at the Jefferies Global Health Conference, which is being held in New York from June 5-7, 2024. The Company's presentation will be on Wednesday, June 5 at 3:00 p ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37719 Corvus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or other jur ...

Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Conference Call May 6, 2024 4:30 PM ET Company Participants Zack Kubow - Real Chemistry Richard Miller - President and CEO, Co-Founder Leiv Lea - Chief Financial Officer Jeffrey Arcara - Chief Business Officer James Rosenbaum - Senior Vice President of Research Ben Jones - Senior Vice President of Regulatory and Pharmaceutical Sciences Conference Call Participants Jeff Jones - Oppenheimer Graig Suvannavejh - Mizuho Securities Liang Cheng - Jefferie ...

Corvus Corporate Presentation Focus on ITK Inhibitors with Broad Opportunities in Cancer & Immune Diseases 2 Corvus ITK Inhibitor Platform Opportunity Strong IP with issued composition patents to Nov 2037; others pending 2nd and 3rd generation compounds with disease selective characteristics Experienced management with proven track record: rituximab, ibrutinib and others 3 Advancing Cancer and Immune Disease Clinical Programs | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------|------- ...

EXHIBIT 99.1 Financial Results Soquelitinib Registration Phase 3 Trial in Peripheral T Cell Lymphoma Advancing Toward Initial Enrollment in Q3 2024 Conference call today at 4:30 p.m. ET / 1:30 p.m. PT "We continue to make strong progress with our two key priorities for the year – advancing soquelitinib for PTCL and generating early data for soquelitinib for atopic dermatitis," said Richard A. Miller, M.D., cofounder, president and chief executive officer of Corvus. "We are encouraged that two newly evaluabl ...

BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on May 6, 2024 at 4:30 pm ET (1:30 pm PT) to provide a business update and report first quarter 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to t ...

Corvus Pharmaceuticals (CRVS) has been on a downward spiral lately with significant selling pressure. After declining 25% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether ...